Demos
Others titles
- VAERS Identification 2022
- Vaccine Adverse Events 2022
- Vaccine Adverse Event Reporting System VAERS Data 2022
Keywords
- Vaccine Adverse Event Reporting System VAERS Data
- VAERS Data
- VAERS Data 2022
- Vaccination Reporting System 2022
- FDA Vaccine Reports
- CDC Vaccine Reports
- Vaccine Side Effects
Vaccine Adverse Event Reporting System 2022
The Vaccine Adverse Event Reporting System (VAERS) 2022 was created by the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) to receive reports about adverse events that may be associated with vaccines. No prescription drug or biological product, such as a vaccine, is completely free from side effects.
Log in to download
Complexity
Get The Data
For getting access to data download links please read and accept the end-user license agreement.
Your Data License
- Research
Non-Commercial, 
Share-Alike, 
Attribution Free Forever - Commercial
Commercial Use, 
Remix & Adapt, 
White Label
Log in to download
Description
Vaccine Adverse Event Reporting System (VAERS) is a passive reporting system, meaning that reports about adverse events are not automatically collected, but require a report to be filed to VAERS. VAERS reports can be submitted voluntarily by anyone, including healthcare providers, patients, or family members. Reports vary in quality and completeness. They often lack details and sometimes can have information that contains errors. About 85-90% of vaccine adverse event reports concern relatively minor events, such as fevers or redness and swelling at the injection site. The remaining reports (less than 15%) describe serious events, such as hospitalizations, life-threatening illnesses, or deaths. The reports of serious events are of greatest concern and receive the most careful scrutiny by VAERS staff. VAERS researchers apply procedures and methods of analysis to help them closely monitor the safety of vaccines. When a concern arises, action is taken. The hope is that this brief explanation of the factors associated with vaccines and adverse events will assist users in understanding the data they are viewing.
Vaccines protect many people from dangerous illnesses, but vaccines, like drugs, can cause side effects, a small percentage of which may be serious. VAERS is used to continually monitor reports to determine whether any vaccine or vaccine lot has a higher than expected rate of events.
About this Dataset
Data Info
| Date Created | 2022 |
|---|---|
| Last Modified | 2022-04-25 |
| Version | 2022-04-25 |
| Update Frequency |
Annual |
| Temporal Coverage |
2022 |
| Spatial Coverage |
United States |
| Source | John Snow Labs; Department of Health and Human Services; |
| Source License URL | |
| Source License Requirements |
N/A |
| Source Citation |
N/A |
| Keywords | Vaccine Adverse Event Reporting System VAERS Data, VAERS Data, VAERS Data 2022, Vaccination Reporting System 2022, FDA Vaccine Reports, CDC Vaccine Reports, Vaccine Side Effects |
| Other Titles | VAERS Identification 2022, Vaccine Adverse Events 2022, Vaccine Adverse Event Reporting System VAERS Data 2022 |
Data Fields
| Name | Description | Type | Constraints |
|---|---|---|---|
| VAERS_Identification_Number | Unique Vaccine Adverse Event Reporting System Identification Number | integer | level : Nominal |
| Received_Date | Date report was received | date | - |
| State_Abbreviation | State Abbreviation | string | - |
| Age_Of_Patient_In_Years | Age of patient in years calculated by (vax_datebirthdate) | number | level : Ratio |
| Age_Of_Patient_In_Months | Age of patient in months calculated by (vax_datebirthdate). The values for this variable range from 0 to <1 | number | level : Ratio |
| Sex | Gender | string | - |
| Date_Form_Completed | Date Form Completed | date | - |
| Reported_Symptom | Detail description for Reported symptom | string | - |
| Is_Died | Died ('Y' = true) | boolean | - |
| Date_Of_Death | Date of Death | date | - |
| Is_Life_Threatening_Illness | Life-Threatening Illness ('Y' - true) | boolean | - |
| Is_Emergency_Room_Or_Doctor_Visit | Emergency Room or Doctor Visit ('Y' - true) | boolean | - |
| Is_Hospitalized | Hospitalized ('Y' - true) | boolean | - |
| Number_Of_Days_Hospitalized | Number of days Hospitalized | integer | level : Ratio |
| Is_Prolonged_Hospitalization | Prolonged Hospitalization ('Y' - true) | boolean | - |
| Is_Disability | Disability ('Y' - true) | boolean | - |
| Is_Recovered | Recovered ('Y' - true, 'N' - false) | boolean | - |
| Vaccination_Date | Vaccination Date | date | - |
| Adverse_Event_Onset_Date | Adverse Event Onset Date | date | - |
| Number_Of_Days | Number of days (Onset date - Vax. Date) | integer | level : Ratio |
| Diagnostic_Laboratory_Data | Diagnostic laboratory data | string | - |
| Vaccines_Administered | Vaccines Administered at (PUB=Public, PVT=Private,OTH=Other, MIL=Military, PHM=Pharmacy or drug store, SCH=School/student health clinic, SEN=Nursing home or senior living facility, WRK=Workplace clinic, UNK=Unknown) | string | - |
| Vaccines_Purchased | Vaccines purchased with (PUB=Public,PVT=Private, OTH=Other, MIL=Military) funds | string | - |
| Other_Medications | Other Medications | string | - |
| Current_Illnesses | Current Illnesses | string | - |
| History | Chronic or long-standing health conditions | string | - |
| Prior_Vaccination_Event_Information | Prior Vaccination Event information | string | - |
| SPLT_Type | Manufacturer or immunization project report number | string | - |
| Form_Vers | VAERS form version 1 or 2 | integer | level : Ratio |
| Todays_Date | Date Form Completed | date | - |
| Is_Birth_Defect | Congenital anomaly or birth defect ('Y' - true) | boolean | - |
| Is_Office_Visit | Doctor or other healthcare provider office or clinic visit ('Y' - true) | boolean | - |
| Is_ER_ED_Visit | Emergency room or department or urgent care ('Y' - true) | boolean | - |
| Allergies | Allergies to medications, food, or other products | string | - |
Data Preview
| VAERS Identification Number | Received Date | State Abbreviation | Age Of Patient In Years | Age Of Patient In Months | Sex | Date Form Completed | Reported Symptom | Is Died | Date Of Death | Is Life Threatening Illness | Is Emergency Room Or Doctor Visit | Is Hospitalized | Number Of Days Hospitalized | Is Prolonged Hospitalization | Is Disability | Is Recovered | Vaccination Date | Adverse Event Onset Date | Number Of Days | Diagnostic Laboratory Data | Vaccines Administered | Vaccines Purchased | Other Medications | Current Illnesses | History | Prior Vaccination Event Information | SPLT Type | Form Vers | Todays Date | Is Birth Defect | Is Office Visit | Is ER ED Visit | Allergies |
| 1996873 | 2022-01-01 | CA | This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. Information regarding the patient's medical history, concurrent conditions or concomitant medications was not provided. On15-DEC-2021, the patient was vaccinated with an expired hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 0.5 mL injection, (lot #R017624, which was considered to be valid, expiration date: 17-MAR-2021), administered for prophylaxis (vaccination scheme frequency, anatomical location and route of administration were not provided) (expired vaccine administered). The reporter stated the vaccine did not experience any temperature excursion. No additional adverse event was reported. | 2021-12-15 | 2021-12-15 | UNK | US0095075132112USA007320 | 2 | 2021-12-31 | ||||||||||||||||||||||||
| 1996874 | 2022-01-01 | SUSPECTED CLINICAL VACCINATION FAILURE; SUSPECTED COVID-19 INFECTION; This spontaneous potential legal report received from a patient concerned a patient of unspecified age and sex. Initial information was processed along with the additional information received from a regulatory authority on 30-DEC-2021. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (dose number in series: 1) (suspension for injection, route of admin not reported, batch number: Unknown and expiry: UNKNOWN) dose, start therapy date were not reported, administered 1 in total for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. It was reported that on an unspecified dates, the patient caught covid twice(coded as suspected covid-19 infection and suspected clinical vaccination failure) and reporter also stated that "If anyone is doing a class action lawsuit against these clowns, hit me up. I want in". The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the suspected covid-19 infection and suspected clinical vaccination failure was not reported. This report was serious (Other Medically Important Condition). This report was associated with a product quality complaint 90000209391. The suspected product quality complaint has been confirmed to be voided(did not meet RA criteria) (as reported complaint was covid with no symptoms and test performed therefore did not meet RA criteria, hence was confirmed as voided) based on the RA evaluation/investigation performed.; Sender's Comments: V0: 20211263430 -Covid-19 vaccine ad26.cov2.s-Suspected clinical Vaccination failure. This event(s) is considered not related. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: SPECIAL SITUATIONS | UNK | USJNJFOC20211263430 | 2 | 2022-01-01 | |||||||||||||||||||||||||||
| 1996875 | 2022-01-01 | OH | male | SUSPECTED CLINICAL VACCINATION FAILURE; SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (dose number in series was 1) (suspension for injection, route of admin not reported, batch number: 204A21A, expiry: UNKNOWN) dose was not reported, 1 total, administered on 11-MAY-2021 in left arm for prophylactic vaccination. No concomitant medications were reported. On 28-DEC-2021, the patient experienced feeling tired, had headaches, fever, stuffy nose, chills, body aches, nasal congestion and cough (suspected covid-19 infection). On 30-DEC-2021, Laboratory data included: COVID-19 antigen test (NR: not provided) positive (suspected clinical vaccination failure). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the suspected clinical vaccination failure and suspected covid-19 infection was not reported. This report was serious (Other Medically Important Condition). This case is associated to product quality complaint.; Sender's Comments: V0- 20211266010-Covid-19 vaccine ad26.CoV-2.s- Suspected clinical vaccination failure. This event is considered not related. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event than the drug. Specifically: SPECIAL SITUATIONS | 2021-12-28 | Test Date: 20211230; Test Name: COVID-19 antigen test; Result Unstructured Data: positive | OTH | USJNJFOC20211266010 | 2 | 2022-01-01 | |||||||||||||||||||||||
| 1996876 | 2022-01-01 | MS | 34.0 | female | Irregular menstrual cycle.; period extremely heavy; bad cramping; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient. A 34 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 18Aug2021 10:00 (Lot number: Fd8448) at the age of 34 years as dose 2,single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: ZOLOFT; ORTHO-TRI-CYCLEN LO. Vaccination history included: Bnt162b2 (Dose: 1, Lot: Ew0176,, Time: 10:00 AM, vaccine location=Left arm), administration date: 28Jul2021, when the patient was 34 years old, for COVID-19 Immunization. The following information was reported: MENSTRUATION IRREGULAR (non-serious) with onset 03Sep2021, outcome "recovering", described as "Irregular menstrual cycle."; HEAVY MENSTRUAL BLEEDING (non-serious) with onset 03Sep2021, outcome "recovering", described as "period extremely heavy"; DYSMENORRHOEA (non-serious) with onset 03Sep2021, outcome "recovering", described as "bad cramping". Therapeutic measures were not taken as a result of menstruation irregular, heavy menstrual bleeding, dysmenorrhoea. Additional Information: Irregular menstrual cycle, which is very unusual for me, especially considering I am on birth control. Began period almost two weeks early, and period extremely heavy with bad cramping. Hospitalization Prolonged was reported as no. Facility where the most recent COVID-19 vaccine was administered was hospital. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.Device Date : 04Sep2021 Follow-up attempts are completed. No further information is expected. | False | 2021-08-18 | 2021-09-03 | 16.0 | PVT | ZOLOFT; ORTHO-TRI-CYCLEN LO | Comments: List of non-encoded Patient Relevant History: Patient Other Relevant History 1: None, Comment: None | USPFIZER INC202101162241 | 2 | 2021-12-31 | ||||||||||||||||||
| 1996877 | 2022-01-01 | CT | female | Breakthrough and heavy periods; longer period length; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 44 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 26Mar2021 09:00 (Lot number: EP6955) as dose 1, single and administered in arm left, administration date 19Apr2021 10:00 (Lot number: ER8731) as dose 2, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ALDACTONE [SPIRONOLACTONE]. The following information was reported: HEAVY MENSTRUAL BLEEDING (non-serious) with onset 07Jun2021, outcome "not recovered", described as "Breakthrough and heavy periods"; OLIGOMENORRHOEA (non-serious) with onset 07Jun2021, outcome "unknown", described as "longer period length". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of heavy menstrual bleeding. Additional Information: Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No, prior to vaccination, was the patient diagnosed with COVID-19. Device Date: 27Sep2021. No follow-up attempts are possible. No further information is expected. | False | 2021-03-26 | 2021-06-07 | 73.0 | Test Date: 20210921; Test Name: Nasal Swab; Result Unstructured Data: Test Result:Negative | PVT | ALDACTONE [SPIRONOLACTONE] | USPFIZER INC202101281356 | 2 | 2021-12-31 | |||||||||||||||||||
| 1996878 | 2022-01-01 | 74.0 | male | tired; Patient reports feeling achy; chills; third dose of the COVID-19 vaccine; This is a spontaneous report received from contactable reporter(s) (Other HCP and Consumer or other non HCP) for a Pfizer sponsored program. A 74 year-old male patient received bnt162b2 (BNT162B2), administration date 23Sep2021 (Batch/Lot number: unknown) at the age of 74 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: IBRANCE, start date: 23Jul2021. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTUERER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (Dose 2; MANUFACTUERER UNKNOWN), for COVID-19 immunization. The following information was reported: FATIGUE (non-serious) with onset Sep2021, outcome "recovered" (2021), described as "tired"; PAIN (non-serious) with onset Sep2021, outcome "recovered" (2021), described as "Patient reports feeling achy"; CHILLS (non-serious) with onset Sep2021, outcome "recovered" (2021), described as "chills". Additional information: Patient reports feeling achy, tired, and chills yesterday, likely due to the third dose of the COVID-19 vaccine administered 23Sep. Patient states he has no side effects today. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected. | True | 2021-09-23 | 2021-09-23 | UNK | IBRANCE | USPFIZER INC202101281503 | 2 | 2021-12-31 | |||||||||||||||||||||
| 1996879 | 2022-01-01 | DE | 78.0 | male | diarrheal discharge of both goop and intestinal matter; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 78 year-old male patient received bnt162b2 (BNT162B2), administration date 15Oct2021 (Lot number: EW0169, Expiration Date: 30Nov2021) at the age of 78 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Thyroid disorder" (unspecified if ongoing), notes: long term thyroid disorder; "Mononucleosis" (unspecified if ongoing), notes: It is Mononucleosis that did not go away.; "All muscles got stiff" (unspecified if ongoing), notes: All muscles got stiff for a couple of days, after the flu shot. It was discomforting.; "discomforting." (unspecified if ongoing), notes: All muscles got stiff for a couple of days, after the flu shot. It was discomforting. Concomitant medication(s) included: FLU, administration date Oct2021. Vaccination history included: Bnt162b2 (DOSE: 1, Batch/lot number: EW0169, Expiry date: 30Nov2021), administration date: 02Feb2021, when the patient was 77 years old, for COVID-19 immunization; Bnt162b2 (DOSE: 2, Lot number: EL9267, Expiry: 31May2021), administration date: 31May2021, when the patient was 78 years old, for COVID-19 immunization. The following information was reported: DIARRHOEA (non-serious) with onset Oct2021, outcome "recovering", described as "diarrheal discharge of both goop and intestinal matter". The event "diarrheal discharge of both goop and intestinal matter" was evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (19Oct2021) unknown result, notes: Nasal test. Therapeutic measures were taken as a result of diarrhoea. No follow-up attempts are possible. No further information is expected. Additional information: This past Friday afternoon and received booster shot for COVID vaccine. Within less than 24 hours he started to experience diarrheal discharge of both goop and intestinal matter. It continued for about a day and a half maybe two. One was to drink Gatorade and he did that and to eat bland stuff. The diarrhea, at least temporarily was discontinuing. The doctors office said to take a container with the stuff to the local clinic in (withheld). He did that this morning. They were not interested and sent him to get COVID tested and he did that. Now they tell him that he would be informed after a couple of days. He was not scheduled for an appointment with a physician today. He did not know if this is over yet. It was not very pleasant. He tried to call VAERS and the only thing they were good for sending him a form to fill out. Caller has no indication it has been reported including at the clinic. He talked with a nurse and got COVID test. It has tapered off after he drank Gatorade and did not eat very much. He has only had a couple of ripe bananas and toast over 24 hour period. And Gatorade that has no sugar. He took a couple Ricola candies and those went down ok. Prior to that he was drinking water and had cut down on medication and practically everything else. Finally he stopped passing whatever. Initially it was coming out like chocolatey goop. Then the very last one occurred last night. After most of it had dissipated, it was a couple of farts and couple of blood drops. He did not notice blood in prior discharges. It got all over everything. Once it was going to come it was going to come. It was not pleasant. From what has been said to him continuing and disabling diarrhea was not associated with booster shot yet. That was what he has heard. Loss of fluid has been pointed out to him several times as a dangerous situation. It has tapered off after he drank Gatorade and did not eat very much. Description of complaint: Caller reporting adverse event with booster shot for COVID vaccine. The reason he got it was because the first and second shot seemed to be very settling for him. With limited medical background, his impression is either the first or second may have settled and activated the immune system with the other viral complications which were documented over the years. That is a wild guess. He w as very surprised there was a reaction to this. It could be an over reaction of immune system. They sent him to get COVID nasal test. In 2 days he will get the results. If for some reason he has acquired disimmunity there will be more questions. No follow-up attempts are possible. No further information is expected. | False | 2021-10-15 | 2021-10-01 | Test Date: 20211019; Test Name: COVID-19 Test; Result Unstructured Data: Test Result:Unknown result; Comments: Nasal test | MIL | Medical History/Concurrent Conditions: Discomfort (All muscles got stiff for a couple of days, after the flu shot. It was discomforting.); Mononucleosis (It is Mononucleosis that did not go away.); Muscle stiffness (All muscles got stiff for a couple of days, after the flu shot. It was discomforting.); Thyroid disorder (long term thyroid disorder) | USPFIZER INC202101405312 | 2 | 2021-12-31 | True | ||||||||||||||||||
| 1996880 | 2022-01-01 | ME | 56.0 | female | Now Lymph node swelling in armpit closest to jab site; Exhaustion; nose running; Sore arm at jab site/jab soreness; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 56 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 17Nov2021 (Lot number: FJ1620) at the age of 56 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "gestational diabetes pre diabetes", start date: 2004 (ongoing), notes: Under control; "Haemophilia- A" (ongoing), notes: from Birth, Under control; "Pre-diabetes" (unspecified if ongoing). Concomitant medication(s) included: SIMVASTATIN taken for blood cholesterol increased, start date: 2021 (ongoing). Vaccination history included: Bnt162b2 (1st Dose, Anatomical site of injection: R upper arm, Route of administration: Intramuscular, batch/ Lot number: EW0150, 31Jul2021), administration date: 02Apr2021, when the patient was 55 years old, for Covid-19 Immunization; Bnt162b2 (2nd Dose, Anatomical site of injection: R upper arm, Route of administration: Intramuscular, batch/ Lot number: EW0176, 31Aug2021), administration date: 23Apr2021, when the patient was 55 years old, for Covid-19 Immunization. The following information was reported: IMMUNISATION (non-serious) with onset 17Nov2021, outcome "unknown", described as "Booster"; VACCINATION SITE PAIN (non-serious) with onset 17Nov2021 21:00, outcome "recovered" (19Nov2021), described as "Sore arm at jab site/jab soreness"; FATIGUE (non-serious) with onset 18Nov2021 08:00, outcome "recovered" (30Nov2021), described as "Exhaustion"; RHINORRHOEA (non-serious) with onset 18Nov2021 08:00, outcome "recovered" (21Nov2021), described as "nose running"; LYMPHADENOPATHY (non-serious) with onset 18Nov2021 10:00, outcome "recovered" (21Nov2021), described as "Now Lymph node swelling in armpit closest to jab site". Therapeutic measures were not taken as a result of vaccination site pain, fatigue, rhinorrhoea, lymphadenopathy. Additional Information: Prior Vaccinations (within 4 weeks): None, Specific relevant tests for thromboembolic events with thrombocytopenia :None. Vaccination Facility Type was PHARMACY, Vaccine was not Administered at Facility. Route of Simvastatin: By Mouth and taken in early 2021. Event: Sore arm at jab site. Exhaustion and nose running began approximately 20 hrs later. Description of Event: Part 2 - yesterday I submitted exhaustion and jab soreness. Now Lymph node swelling in armpit closest to jab site. Follow-up attempts are completed and no further information is expected | True | 2021-11-17 | 2021-11-17 | PHM | SIMVASTATIN | Gestational diabetes (Under control); Haemophilia A (from Birth Under control) | Medical History/Concurrent Conditions: Pre-diabetes | USPFIZER INC202101631436 | 2 | 2021-12-31 | ||||||||||||||||||
| 1996881 | 2022-01-01 | NY | my torso was covered with a rash/rash spreadof over my entire body/she developed widespread, sevre erythrodermic skin eruption; She had skin biopsy conforming lichenoid drug eruption; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP and Other HCP) for a Pfizer sponsored program. The reporter is the patient. A patient (no qualifiers provided) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 14Apr2021 13:00 (Lot number: ER8731) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Anxiety /Depression", start date: 2009 (ongoing); "Anxiety /Depression", start date: 2009 (ongoing); "Hysterectomy", start date: 2011 (unspecified if ongoing), notes: Pertinent details: Hysterectomy. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose:1, single, Time:01:00 PM, Anatomical site of injection: Left arm, Route of administration: Intramuscular, Batch/Lot number: ER2613), administration date: 24Mar2021, for COVID-19 Immunization. The following information was reported: RASH (medically significant) with onset Apr2021, outcome "recovered" (2021), described as "my torso was covered with a rash/rash spreadof over my entire body/she developed widespread, sevre erythrodermic skin eruption"; DRUG ERUPTION (non-serious) with onset 2021, outcome "unknown", described as "She had skin biopsy conforming lichenoid drug eruption". The event "my torso was covered with a rash/rash spreadof over my entire body/she developed widespread, sevre erythrodermic skin eruption" was evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: biopsy: (2021) having a reaction to a medication, notes: A biopsy was taken from my skin is and it was determined I was having a reaction to a medication; biopsy skin: (23Sep2021) lichenoid dermatitis, notes: Lichenoid Dermatitis, compatible with lichenoid drug eruption. Therapeutic measures were taken as a result of rash. | True | 2021-04-14 | 2021-04-01 | Test Date: 2021; Test Name: biopsy; Result Unstructured Data: Test Result:having a reaction to a medication; Comments: A biopsy was taken from my skin is and it was determined I was having a reaction to a medication.; Test Date: 20210923; Test Name: Skin Punch Biopsy; Result Unstructured Data: Test Result:Lichenoid Dermatitis; Comments: Lichenoid Dermatitis, compatible with lichenoid drug eruption | OTH | Anxiety; Depression | Medical History/Concurrent Conditions: Hysterectomy (Pertinent details: Hysterectomy) | USPFIZER INC202101639762 | 2 | 2021-12-31 | True | |||||||||||||||||||
| 1996882 | 2022-01-01 | 71.0 | male | pyrexia; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). A 71 year-old male patient received bnt162b2 (COMIRNATY), administration date Jan2021 (Batch/Lot number: unknown) at the age of 71 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PYREXIA (non-serious), outcome "unknown", described as "pyrexia". Additional information: the patient didn't get any pain after the first dose. It was only after the second dose. Caller doesn't recall patient having any severe reactions with either dose. Patient had some pyrexia, the usual things that a person gets after the first and second dose. Patient was not really sick. Thinks patient got chills and fever and it went away. Nothing that caller would think was unusual. Attempted to clarify dates regarding fever, pyrexia, and chills. Caller doesn't know when this occurred or after which dose. Caller just remembers patient saying he was going to bed because he was cold. Attempted to clarify dates of Comirnaty vaccines: Caller had her first dose in Dec2020 and second dose in Jan2021. She thinks the patient had his first dose in middle of Jan2021 and second dose in Feb2021. Caller does not have patient's record card to provide any information about patient's Comirnaty vaccines. Indication: Both caller and the patient are in the medical field. They both see patients. Patient still walks around like he was a man from Mars. A couple months later, caller has not seen patient put the Volatren on. States it's regular. Patient mentioned recently that he should see someone about the pain, which was unlike him. Caller thinks the pain must be bothering the patient significantly. Caller doesn't know if patient was having pain or if patient was frustrated. Caller decided on her own to call and report this to Pfizer. Patient had the booster dose just recently. Doesn't believe patient's pain has gotten any worse since the booster shot, but she hasn't actually asked the patient that. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected. | 2021-01-01 | UNK | USPFIZER INC202101649903 | 2 | 2021-12-31 |